Hematology

The addition of abemaciclib to fulvestrant appeared to effectively improve progression-free survival.

High yogurt intake may protect against breast cancer, while processed cheeses may increase cancer risk.

Mapping lung cancer cell interactions can unveil new targeted treatment techniques.

Vitamin C observed to kill cancer stem-like cells.

Nanomachines produce a florescent response when in contact with cancer biomarkers.

Muscle composition may be predictive of chemotherapy toxicity.

Clinical practice guideline on human papillomavirus (HPV) vaccination can improve prevention of cervical cancer.

The risk of a second cancer remained high even 30 years after treatment.

Top news of the week in oncology and cancer drug development.

Researchers analyzed tumors and treated them with a targeted therapy.

A combination drug regimen may be the answer to treating acute myeloid leukemia.

Top news of the day from across the health care landscape.

Top news of the day from across the healthcare landscape.

BET-inhibitors and immune-based treatments may improve outcomes in patients with blood cancer.

Patients with specific stem cell mutations may be at an increased risk of acute myeloid leukemia.

Protein once thought to suppress tumors in acute myeloid leukemia may instead promote the disease.

Promise seen in targeting protein in PTEN-deficient cancer cells.

TG Therapeutics’ investigational combination leukemia drug TG-1101 (ubilituximab), used with approved treatment Imbruvica (ibrutinib), showed positive results in a late-stage clinical trial.

Treatment with the myxoma virus reduced tumor burden and led to a modest decrease in disease progression in mice.

Top news of the week in oncology and cancer drug development.

PI3K inhibitors loaded into nanoparticles provided targeted treatment for head and neck cancers.

Drug may offer an effective alternative to chemotherapy for patients with leukemia.

Enasidenib is a targeted inhibitor of mutated isocitate dehydrogenase.

Investigational drug treats patients with relapsed or refractory AML with an isocitrate dehydrogenase 2 mutation.

Marc O'Connor, COO and chief strategy officer at Curant Health, discusses how the shift to Medicare Part D could impact patients undergoing treatment for cancer.